Jianfeng Shu

Zhejiang Wanli University — China

Medicine · Health Sciences

11h-index402citations24works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(6), Cancer therapeutics and mechanisms(6), RNA modifications and cancer(5), Ferroptosis and cancer prognosis(4), Ubiquitin and proteasome pathways(3)

Publications24 total

Video‐Assisted Thoracoscopic Left Lower Lobectomy and Bronchial Foreign Body Removal for Treating a Rare Occult Bronchial Foreign Body in an Adult
Respirology Case Reports·2025· 1 citedOpen Access
Correction to “Olink Proteomics-Based Exploration of Immuno-Oncology-Related Biomarkers Leading to Lung Adenocarcinoma Progression”
Journal of Proteome Research·2025
Research progress on the regulation mechanism of DEPTOR expression and its role in tumorigenesis
Neoplasma·2025· 1 citedOpen Access
Olink Proteomics-Based Exploration of Immuno-Oncology-Related Biomarkers Leading to Lung Adenocarcinoma Progression
Journal of Proteome Research·2024· 2 cited
Correction: MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
Cell Death and Disease·2024Open Access
Author Correction: ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms
Scientific Reports·2024Open Access
MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner
Cell Death and Disease·2024· 2 citedOpen Access
Construction of RNA Methylation Modification-immune-relatedlncRNA Molecular Subtypes and Prognostic Scoring System in LungAdenocarcinoma
Current Medicinal Chemistry·2023· 7 cited
Author Correction: ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms
Scientific Reports·2023Open Access
Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis
Frontiers in Immunology·2023· 38 citedOpen Access
ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms
Scientific Reports·2023· 19 citedOpen Access
Effect of Somatosensory Interaction Transcutaneous Electrical Acupoint Stimulation on Cancer-related Fatigue and Immunity
American Journal of Clinical Oncology·2022· 5 citedOpen Access
Induction of p27 contributes to inhibitory effect of isorhapontigenin (ISO) on malignant transformation of human urothelial cells
Cell Cycle·2022· 5 citedOpen Access
Acupoint Selection for Autonomous Massage Based on Infrared Thermography
Traitement du signal·2022· 7 citedOpen Access
Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy
Molecular Biology Reports·2021· 29 citedOpen Access
DEPTOR inhibits lung tumorigenesis by inactivating the EGFR-mTOR signals
Cancer Letters·2021· 17 citedOpen Access
SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II
Oncogenesis·2020· 19 citedOpen Access
FBXW7 Confers Radiation Survival by Targeting p53 for Degradation
Cell Reports·2020· 78 citedOpen Access
DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals
Oncogene·2019· 44 citedOpen Access
The cross talk of two family members of β-TrCP in the regulation of cell autophagy and growth
Cell Death and Differentiation·2019· 48 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Danrui Cui(6), Xiufang Xiong(6), Yongchao Zhao(6), Xuejie Yang(5), Xiaofang Wang(4), Xiao-Qing Dai(3), Yi Sun(3), Ying Ma(3), Yanli Bi(3), Jinni Jiang(3), Guofang Zhao(3), Guofang Zhao(3), Dongping Wei(2), Xiaoyu Chen(2), Longyuan Gong(2), Ye Feng(2), Zhi Ruan(2), Guofang Zhao(2), Aixiang Jin(2), Shu Chen(2)